A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension

• Status: ACTIVE_NOT_RECRUITING
• Trial end date: 2028-05-22

Summary

This study is to assess the pharmacokinetics (PK) and safety of SC pembrolizumab (+) berahyaluronidase alfa vs intravenous (IV) pembrolizumab, administered with chemotherapy in first line treatment of adult Japanese participants with metastatic non-small cell lung cancer. The primary hypotheses of this study are pembrolizumab (+) berahyaluronidase alfa subcutaneous (SC) is noninferior to pembrolizumab IV with respect to PK parameters.

• Phase: PHASE3

Details

• Lead Sponsor: Merck Sharp & Dohme LLC
• Treatments: 130-nm albumin-bound paclitaxel; Albumin-Bound Paclitaxel; Carboplatin; Cisplatin; Filgrastim; Paclitaxel; pembrolizumab; Pemetrexed